Clinical trials for Antifungal medicines

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Antifungal medicines. For all clinical trials, go to clinical trials search

This list shows clinical trials for Antifungal medicines

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Antifungal medicines
Title Recruitment status Location
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN AS ANTIFUNGAL TREATMENT IN PATIENTS WITH INVASIVE CANDIDIASIS OR CANDIDEMIA Not Recruiting United Kingdom
An adaptive pharmacological approach for the individualisation of voriconazole antifungal therapy Not Recruiting United Kingdom
Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT) Not recruiting United Kingdom
Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy Not recruiting United Kingdom
Antifungal shampoo for the treatment of pityriasis capitis (severe dandruff) and scalp seborrhoeic dermatitis Not Recruiting United Kingdom
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia Not recruiting United Kingdom
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN AS ANTIFUNGAL TREATMENT IN PATIENTS WITH INVASIVE CANDIDIASIS OR CANDIDEMIA Not Recruiting United Kingdom
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN AS ANTIFUNGAL TREATMENT IN PATIENTS WITH INVASIVE CANDIDIASIS OR CANDIDEMIA Not Recruiting United Kingdom
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN AS ANTIFUNGAL TREATMENT IN PATIENTS WITH INVASIVE CANDIDIASIS OR CANDIDEMIA Authorised United Kingdom
Study to test effectiveness and safety of a new drug, SCY-078 in patients with fungal diseases who do not easily respond to, or who are intolerant to, the current treatment for their disease. Authorised United Kingdom

Page last reviewed: 18/08/2024

Next review due: 18/08/2024